SEER, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.91 USD | +9.14% |
|
+15.06% | -1.55% |
| 02-29 | Transcript : Seer, Inc., Q4 2023 Earnings Call, Feb 29, 2024 | |
| 02-29 | Seer, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 18.94M 1.52B | Sales 2025 * | 28.57M 2.29B | Capitalization | 124M 9.93B |
|---|---|---|---|---|---|
| Net income 2024 * | -86M -6.88B | Net income 2025 * | -86M -6.88B | EV / Sales 2024 * | -8.44 x |
| Net cash position 2024 * | 284M 22.72B | Net cash position 2025 * | 251M 20.08B | EV / Sales 2025 * | -4.44 x |
| P/E ratio 2024 * |
-1.53
x | P/E ratio 2025 * |
-1.62
x | Employees | 147 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on Seer, Inc.
More recommendations
More press releases
| 1 day | +9.14% | ||
| 1 week | +15.06% | ||
| Current month | +0.53% | ||
| 1 month | -1.55% | ||
| 3 months | +7.91% | ||
| 6 months | +13.02% | ||
| Current year | -1.55% |
1 week
1.61
1.95
1 month
1.611.95
Current year
1.512.18
1 year
1.465.65
3 years
1.4653.42
5 years
1.4686.55
10 years
1.4686.55
| Managers | Title | Age | Since |
|---|---|---|---|
Omid Farokhzad
CEO | Chief Executive Officer | 55 | 15/03/17 |
David Horn
DFI | Director of Finance/CFO | 56 | 30/04/20 |
Ross Kenny
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Terry McGuire
BRD | Director/Board Member | 68 | 30/11/17 |
Robert Langer
FOU | Founder | 75 | 15/03/17 |
David Hallal
BRD | Director/Board Member | 57 | 31/01/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.91 | +9.14% | 957,441 |
| 25/04/24 | 1.75 | -1.13% | 259,123 |
| 24/04/24 | 1.77 | -2.21% | 207,641 |
| 23/04/24 | 1.81 | +8.38% | 1,543,371 |
| 22/04/24 | 1.67 | +0.60% | 727,767 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Sector
Office Equipment
Calendar
07/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.91
USD
Average target price
7
USD
Spread / Average Target
+266.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.55% | 124M | |
| +7.13% | 7.91B | |
| -3.15% | 4.66B | |
| -9.18% | 2.84B | |
| +1.11% | 2.03B | |
| -26.56% | 1.12B | |
| -22.71% | 759M | |
| -13.49% | 755M | |
| -56.85% | 682M | |
| -24.66% | 671M |
- Stock Market
- Equities
- SEER Stock
